What is 80% of a 44‑unit dose of SOLIQUA (insulin glargine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

80% of SOLIQUA 44 Units = 35.2 Units

When converting from a 44-unit dose of SOLIQUA 100/33 to 80% of that dose, administer 35.2 units (round to 35 units in clinical practice).

Understanding SOLIQUA Dosing

SOLIQUA 100/33 is a fixed-ratio combination product containing:

  • 100 units/mL of insulin glargine
  • 33 mcg/mL of lixisenatide

This means each unit of SOLIQUA delivers both 1 unit of insulin glargine AND 0.33 mcg of lixisenatide simultaneously 1.

The 80% Dose Reduction Context

The 80% dose reduction principle appears in multiple clinical scenarios in the diabetes guidelines:

When Converting NPH Insulin Regimens

When transitioning from bedtime NPH to twice-daily NPH or to a basal-bolus regimen, the total NPH dose should be reduced to 80% of the current dose 2, 3. This reduction helps prevent hypoglycemia during regimen intensification.

Application to SOLIQUA

For your specific calculation with SOLIQUA:

  • Starting dose: 44 units
  • 80% of 44 units: 44 × 0.80 = 35.2 units
  • Practical dose: Round to 35 units

Clinical Context for Dose Reductions

Common scenarios requiring dose reduction to 80%:

  • Transitioning insulin regimens to prevent hypoglycemia during the adjustment period 2
  • Converting from bedtime to split-dose regimens where insulin distribution changes 3
  • Adding prandial insulin when A1C is <8% (<64 mmol/mol), consider lowering basal by 10% or 4 units 2

Important Caveats

Monitor closely after any dose reduction:

  • Check fasting plasma glucose to ensure adequate basal coverage
  • Assess for hyperglycemia that may require dose re-escalation
  • For hypoglycemia without clear cause, reduce dose by 10-20% 2

SOLIQUA-specific considerations:

  • The fixed ratio means you cannot independently adjust insulin glargine vs. lixisenatide components 1
  • Maximum dose is 60 units daily (60 units insulin glargine/20 mcg lixisenatide) 1
  • Dose adjustments should target fasting plasma glucose <100 mg/dL 1

Related Questions

How should the dose be adjusted when switching from insulin glargine 100 U (Lantus) to insulin glargine 300 U (Toujeo)?
Is it reasonable to increase insulin glargine (Lantus) from 16 units to 20 units in a single step?
Can an adult with diabetes who is stable on basal insulin and has no known insulin glargine allergy temporarily substitute Basaglar (insulin glargine) with Lantus (insulin glargine) at the same dose?
How should I convert a regimen of 20 units twice daily of premixed 70/30 insulin to insulin glargine (Lantus)?
How should I adjust insulin therapy for a patient on Lantus Solostar (insulin glargine) 26 units twice daily with blood glucose consistently in the 300‑400 mg/dL range and occasional morning lows to 140 mg/dL?
Does tart cherry juice contain resveratrol?
What is the appropriate dosing of amoxicillin‑clavulanate (Augmentin) or amoxicillin for a susceptible Escherichia coli urinary tract infection with bacteremia in an adult with normal renal function?
How can I differentiate Helicobacter pylori infection, peptic ulcer disease, and non‑ulcer gastritis in a patient with epigastric pain, nausea, early satiety, and dyspepsia, and what are the recommended diagnostic and treatment steps?
Is it safe for a 13-year-old adolescent to use a 7 mg nicotine patch daily?
What lipid‑lowering therapy is appropriate for a statin‑intolerant patient on ezetimibe (Zetia) with triglycerides 505 mg/dL, given that fenofibric acid (fenofibrate) is not covered by insurance?
Do oligomeric proanthocyanidin (OPC) supplements contain resveratrol?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.